Sanofi's second medical use patent revoked by UPC in win for generics

Sanofi lost its second medical use patent for an established cancer drug at the Unified Patent Court to three generic companies: Stada, Dr. Reddy's, and Zentiva. The UPC revoked the patent in a ruling published Tuesday, suggesting the court may take a stricter approach than the European Patent Office toward second medical-use patents. The decision represents a victory for generic pharmaceutical companies challenging Sanofi's intellectual property rights.